A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer. Shah YB, Shaver AL, Kelly WK, Lu-Yao G, et al. PLoS One 2022;17:e0273826.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shah YB, Shaver AL, Kelly WK, Lu-Yao G, et al. A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer. PLoS One 2022;17:e0273826.
PMID: 36037225